Silodosin Responsive Benign Prostatic Hyperplasia Therapeutics
1. Rapaflo patent expiration
Treatment: Use in the treatment of the signs and symptoms of benign prostatic hyperplasia (bph)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6015819 | ABBVIE | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(13 years ago) | |
| US5387603 | ABBVIE | 1,5,7-trisubstituted indoline compounds and salts thereof |
Dec, 2018
(7 years ago) | |
| US5403847 | ABBVIE | Use of α1C specific compounds to treat benign prostatic hyperlasia |
Nov, 2012
(13 years ago) | |
| US5780485 | ABBVIE | Use of α1c specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2013 |
Drugs and Companies using SILODOSIN ingredient
NCE-1 date: 08 October, 2012
Market Authorisation Date: 08 October, 2008
Dosage: CAPSULE
How can I launch a generic of RAPAFLO before it's drug patent expiration?
More Information on Dosage
RAPAFLO family patents
